EP2802652A4 - Enzymes de clostridium histolyticum et procédés pour les utiliser - Google Patents
Enzymes de clostridium histolyticum et procédés pour les utiliserInfo
- Publication number
- EP2802652A4 EP2802652A4 EP13736040.0A EP13736040A EP2802652A4 EP 2802652 A4 EP2802652 A4 EP 2802652A4 EP 13736040 A EP13736040 A EP 13736040A EP 2802652 A4 EP2802652 A4 EP 2802652A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- enzymes
- methods
- clostridium histolyticum
- histolyticum
- clostridium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 241000193159 Hathewaya histolytica Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
- G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
- G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
- G01N2333/96419—Metalloendopeptidases (3.4.24)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Virology (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19174182.6A EP3584317B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
DK19174182.6T DK3584317T5 (da) | 2012-01-12 | 2013-01-10 | Clostridium histolyticum enzym |
EP23185957.0A EP4276180A3 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP21208743.1A EP4015627B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261585909P | 2012-01-12 | 2012-01-12 | |
PCT/US2013/020940 WO2013106510A2 (fr) | 2012-01-12 | 2013-01-10 | Enzymes de clostridium histolyticum et procédés pour les utiliser |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23185957.0A Division EP4276180A3 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP21208743.1A Division EP4015627B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP19174182.6A Division EP3584317B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2802652A2 EP2802652A2 (fr) | 2014-11-19 |
EP2802652A4 true EP2802652A4 (fr) | 2015-10-14 |
EP2802652B1 EP2802652B1 (fr) | 2019-06-05 |
Family
ID=48782075
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13736040.0A Active EP2802652B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP21208743.1A Active EP4015627B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP23185957.0A Pending EP4276180A3 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP19174182.6A Active EP3584317B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21208743.1A Active EP4015627B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP23185957.0A Pending EP4276180A3 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
EP19174182.6A Active EP3584317B1 (fr) | 2012-01-12 | 2013-01-10 | Enzyme de clostridium histolyticum |
Country Status (13)
Country | Link |
---|---|
US (4) | US9757435B2 (fr) |
EP (4) | EP2802652B1 (fr) |
JP (5) | JP6263755B2 (fr) |
AU (6) | AU2013208028B2 (fr) |
BR (1) | BR112014017229B1 (fr) |
CA (2) | CA2970639C (fr) |
DK (2) | DK2802652T3 (fr) |
ES (3) | ES2968836T3 (fr) |
HU (2) | HUE057423T2 (fr) |
MX (1) | MX351448B (fr) |
NZ (5) | NZ766918A (fr) |
PT (2) | PT2802652T (fr) |
WO (1) | WO2013106510A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2816009T3 (es) * | 2011-12-14 | 2021-03-31 | Univ Arkansas | Administración de agentes terapéuticos mediante una proteína de unión a colágeno |
DK2802652T3 (da) | 2012-01-12 | 2019-07-15 | Endo Global Ventures | Clostridium histolyticum enzym |
RU2540919C1 (ru) * | 2013-09-27 | 2015-02-10 | Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" | Способ безоперационного лечения контрактуры дюпюитрена iii-iv степени тяжести |
PT107276B (pt) * | 2013-11-07 | 2018-06-07 | Univ Aveiro | Método para produção de colagenase recombinante para digestão de colagénios |
WO2017074257A1 (fr) * | 2015-10-26 | 2017-05-04 | Nanyang Technological University | Dérivés non viables de clostridium sporogenes utilisés comme agents thérapeutiques anti-cancéreux |
WO2018104540A1 (fr) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Arn pour la cicatrisation des plaies |
JP2020501545A (ja) * | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのrna |
JP7397440B2 (ja) | 2017-02-10 | 2023-12-13 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | コラーゲン結合薬剤組成物およびその使用方法 |
AU2018226820B2 (en) | 2017-03-01 | 2022-12-08 | Endo Ventures Limited | Apparatus and method for assessing and treating cellulite |
EP3601556A2 (fr) | 2017-03-28 | 2020-02-05 | Endo Ventures Limited | Methode amelioree de production de la collagenase |
CZ308157B6 (cs) | 2017-09-13 | 2020-01-29 | MB PHARMA s.r.o. | Kmen bakterie Clostridium histolyticum, kolagenáza připravená s použitím tohoto kmene a její použití |
WO2020021332A2 (fr) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Techniques d'injection pour le traitement de la cellulite |
WO2020021330A2 (fr) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Techniques d'injection pour le traitement de la cellulite |
KR20210079291A (ko) | 2018-09-18 | 2021-06-29 | 엔도 글로벌 에스테틱스 리미티드 | 셀룰라이트를 치료하기 위한 조성물 및 방법 |
CN109355222B (zh) * | 2018-11-06 | 2020-06-02 | 上海交通大学 | 对水稻白叶枯病菌具有拮抗作用的芽孢杆菌及分离与应用 |
CN113382714A (zh) | 2019-01-06 | 2021-09-10 | 恩多全球美学有限公司 | 胶原酶制剂及其制备方法 |
CN113474355A (zh) * | 2019-02-14 | 2021-10-01 | 诺尔玛克制药有限公司 | 从i型胶原酶、ii型胶原酶、中性蛋白酶和梭菌蛋白酶选出的至少一种酶的色谱纯化 |
CN113025599B (zh) * | 2021-04-02 | 2023-09-12 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌i型胶原酶及其制备方法和应用 |
CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
WO2023112020A1 (fr) * | 2021-12-14 | 2023-06-22 | Ramot At Tel Aviv University Ltd. | Collagénase recombinante modifiée, compositions les comprenant et leurs utilisations dans des procédures dentaires |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007089851A2 (fr) * | 2006-01-30 | 2007-08-09 | Auxilium International Holdings, Inc. | Compositions et procedes de traitement des maladies mediees par le collagene |
WO2011073925A2 (fr) * | 2009-12-15 | 2011-06-23 | Abiel S.R.L. | Collagénases de recombinaison de c. histolyticum et procédé de production de ces dernières |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3821364A (en) * | 1966-07-08 | 1974-06-28 | Advance Biofactures Corp | Process of producing collagenase |
JPS5662229A (en) | 1979-10-25 | 1981-05-28 | Asahi Glass Co Ltd | Electro-optical dimming panel |
US4338300A (en) | 1981-02-05 | 1982-07-06 | The Regents Of The University Of California | Use of purified clostridial collangenase in the treatment of Peyronie's disease |
EP0115974B1 (fr) | 1983-01-05 | 1988-09-07 | Institut Pasteur | Préparation à activité collagénolytique ayant une activité élevée et compositions pharmaceutiques la contenant |
US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
US4524065A (en) | 1983-08-04 | 1985-06-18 | Bio-Specifics N.V. | Method for the prevention and treatment of scars with enzymes |
US4542065A (en) | 1984-05-21 | 1985-09-17 | Ppg Industries, Inc. | Chemically treated glass fibers and strands and dispersed products thereof |
JPS61289885A (ja) | 1985-06-14 | 1986-12-19 | Nitta Zerachin Kk | コラゲナ−ゼおよびコラゲナ−ゼの製造方法 |
JP2898022B2 (ja) | 1989-09-05 | 1999-05-31 | 株式会社ニッピ | コラーゲン分解酵素の製造方法 |
US5252461A (en) | 1990-05-01 | 1993-10-12 | The Regents Of The Univ. Of California | Mixed immunoglobulins for detection of rheumatoid factors |
CA2047306A1 (fr) | 1990-07-23 | 1992-01-24 | Milan Holjevac | Mutant de clostridium histolyticum, procede permettant de l'obtenir et utilisation de celui-ci pour la production de collagenase exempte de clostripain |
US5393792A (en) | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
US5462739A (en) | 1991-11-21 | 1995-10-31 | Yeda Research And Development Co., Ltd. | Microdelivery device and method for enhanced drug administration to the eye |
US5256140A (en) | 1992-03-27 | 1993-10-26 | Fallien Cosmeceuticals, Ltd. | Composition for levelling skin |
CA2138948A1 (fr) * | 1992-06-22 | 1994-01-06 | Hun-Chi Lin | Clonage moleculaire des genes de la production de collagenase par clostridium histolyticum |
JP3553065B2 (ja) | 1992-12-30 | 2004-08-11 | バイオテクノロジスク インスティテュート | 挿入プロモーター含有の組換え乳酸菌とその構築方法 |
JP3186881B2 (ja) | 1993-02-18 | 2001-07-11 | 倉敷紡績株式会社 | 肝細胞の分離方法 |
US5332503A (en) | 1993-04-16 | 1994-07-26 | Baxter International Inc. | Process for purifying collagenase |
US5514340A (en) | 1994-01-24 | 1996-05-07 | Magnetix Biotechnology, Inc. | Device for separating magnetically labelled cells |
WO1996000283A1 (fr) | 1994-06-24 | 1996-01-04 | Boehringer Mannheim Corporation | Melange purifie de collagenases et de deux autres proteases tirees de clostridium histolyticum |
US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
CA2158822C (fr) | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Agent therapeutique pour maladie rhumatismale |
US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
US6146626A (en) | 1995-03-16 | 2000-11-14 | Knoll Aktiengesellschaft | Defined enzyme mixtures for obtaining cells and treating wounds |
US5705170A (en) | 1995-10-24 | 1998-01-06 | Plantech International, Inc. | Herbal cellulite treatments |
US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
ES2185972T3 (es) | 1996-09-06 | 2003-05-01 | Bioteknologisk Inst | Sistema de expresion regulable en bacterias productoras de acido lactico. |
JP2001510331A (ja) * | 1996-11-19 | 2001-07-31 | ロシュ ダイアグノスティックス ゲーエムベーハー | クロストリジウム・ヒストリチカム由来の組換えコラゲナーゼタイプ▲i▼および細胞と細胞群の単離へのその使用 |
US5830741A (en) | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
US5753785A (en) | 1996-12-16 | 1998-05-19 | Fina Technology, Inc. | Production of E-B copolymers with a single metallocene catalyst and a single monomer |
US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
JPH10262658A (ja) | 1997-03-28 | 1998-10-06 | Kikkoman Corp | ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造 |
WO1999017738A1 (fr) | 1997-10-03 | 1999-04-15 | Lavipharm Laboratories, Inc. | Composition a base de prolamines et de lipides polaires d'origine vegetale, procede de fabrication et applications |
GB9724802D0 (en) | 1997-11-24 | 1998-01-21 | Unilever Plc | Antiperspirant or deodorant compoistions |
US20020036328A1 (en) | 1998-11-16 | 2002-03-28 | William R. Richards, Jr. | Offset drain fermi-threshold field effect transistors |
FR2788682B1 (fr) | 1999-01-26 | 2001-04-06 | Seb Sa | Dispositif de thermographie |
US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
RU2180002C2 (ru) | 1999-08-16 | 2002-02-27 | Пермское научно-производственное объединение "Биомед" | Способ получения коллагеназы |
WO2001013865A1 (fr) | 1999-08-20 | 2001-03-01 | Howard Murad | Compositions et methodes pharmaceutiques de reduction de l'apparition de la cellulite |
US6280993B1 (en) * | 1999-08-24 | 2001-08-28 | Ichiro Yamato | Gene encoding class I collagenase |
ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
WO2001021574A1 (fr) | 1999-09-24 | 2001-03-29 | Johns Hopkins University | Systemes et techniques permettant d'ouvrir des voies biologiques obstruees |
US7811250B1 (en) | 2000-02-04 | 2010-10-12 | Boston Scientific Scimed, Inc. | Fluid injectable single operator exchange catheters and methods of use |
EP1187602A4 (fr) | 2000-04-18 | 2004-09-15 | Peptron Inc | Composition pharmaceutique injectable a liberation durable et procedes de preparation de celle-ci |
NZ525394A (en) | 2000-10-20 | 2005-12-23 | Bioneer As | Improved fermentation method for production of heterologous gene products in lactic acid bacteria |
CA2432797C (fr) | 2000-12-18 | 2014-02-04 | David J. Yang | Chimiotherapie et radiotherapie regionales locales au moyen d'un hydrogel in situ |
WO2002060410A2 (fr) | 2001-01-30 | 2002-08-08 | The Regents Of The University Of Michigan | Methodes d'administration locale a liberation prolongee de medicaments visant a l'ablation de tissus non desires |
CA2447818C (fr) | 2001-07-02 | 2011-01-04 | Nordmark Arzneimittel Gmbh & Co. Kg | Procede de purification d'une enzyme, enzyme ainsi produite et purifiee et utilisation de cette enzyme |
GB0124124D0 (en) | 2001-10-08 | 2001-11-28 | Medical Res Council | Methods of treatment |
JP2003284553A (ja) | 2002-03-28 | 2003-10-07 | Seikagaku Kogyo Co Ltd | 生理活性タンパク質 |
BR0215785A (pt) | 2002-06-25 | 2006-06-06 | Ultrashape Inc | dispositivos e metodologias uteis para esteticas do corpo |
EP1433845A1 (fr) * | 2002-12-23 | 2004-06-30 | Georg-August-Universität | Collagenase de Clostridium tetani et utilisations |
EP1462519A1 (fr) | 2003-03-24 | 2004-09-29 | Boehringer Ingelheim Austria GmbH | Méthodes et appareilles pour la production de molécules biologiques |
JP4205496B2 (ja) | 2003-06-19 | 2009-01-07 | 三菱化学株式会社 | 新規カルボニル還元酵素及びこれをコードするdna、ならびにこれらを利用した光学活性アルコールの製造方法 |
US7842673B2 (en) | 2003-12-17 | 2010-11-30 | The Trustees Of Columbia University In The City Of New York | Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA |
NZ576986A (en) | 2004-01-30 | 2010-12-24 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
MXPA06011463A (es) | 2004-04-07 | 2007-04-25 | Rinat Neuroscience Corp | Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio. |
US7754230B2 (en) | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
PL2422789T3 (pl) | 2004-05-19 | 2018-09-28 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Wstrzykiwalna kompozycja zawierająca deoksycholan sodu |
US7355027B2 (en) | 2004-06-16 | 2008-04-08 | Dynport Vaccine Company Llc | Bacillus anthracis protective antigen |
DE602005014117D1 (de) | 2004-07-07 | 2009-06-04 | Lundbeck As Valby H | Neues carbamyliertes epo und verfahren zu dessen herstellung |
JP2008505928A (ja) | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
US20060020448A1 (en) | 2004-07-21 | 2006-01-26 | Microsoft Corporation | Method and apparatus for capitalizing text using maximum entropy |
WO2006025226A1 (fr) | 2004-08-30 | 2006-03-09 | Daicel Chemical Industries, Ltd. | Monoéthers de polyglycérol et processus de production |
JP4923131B2 (ja) | 2004-08-30 | 2012-04-25 | 株式会社リコー | ログ収集システム、ログ収集装置およびログ収集プログラム |
US20150025420A1 (en) | 2004-10-06 | 2015-01-22 | Guided Therapy Systems, Llc | Ultrasound treatment device and methods of use |
DE102004060075A1 (de) | 2004-12-14 | 2006-07-06 | Merck Patent Gmbh | Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt |
US7854929B2 (en) | 2005-01-21 | 2010-12-21 | The Research Foundation Of State University Of New York | Method for treating lateral epicondylitis using collagenase |
US20060204488A1 (en) | 2005-01-21 | 2006-09-14 | Badalamente Marie A | Methods for treating adhesive capsulitis |
US20070224184A1 (en) | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
JP2006254876A (ja) | 2005-03-18 | 2006-09-28 | Hokkaido Univ | L−トリプトファン製造法 |
US20060241673A1 (en) | 2005-04-21 | 2006-10-26 | Zadini Filiberto P | Subcision device |
US20060251581A1 (en) | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
US20070003541A1 (en) | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for therapeutics |
ITPD20050207A1 (it) | 2005-07-07 | 2007-01-08 | Fidia Farmaceutici | Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere |
US20070031482A1 (en) | 2005-08-02 | 2007-02-08 | Ceramoptec Industries, Ind. | PDT treatment method for cellulites and cosmetic use |
WO2007100590A2 (fr) | 2006-02-22 | 2007-09-07 | Auxilium Pharmaceuticals, Inc. | Procédés de traitement de la cellulite |
EA200802090A1 (ru) | 2006-03-31 | 2010-04-30 | ДСМ АйПи АССЕТС Б.В. | Новое применение соединений и комбинаций соединений для улучшения внешнего вида |
US20080233614A1 (en) | 2007-02-13 | 2008-09-25 | Cranenburgh Rocky M | Production of recombinant collagenases colg and colh in escherichia coli |
US8617543B2 (en) | 2007-02-14 | 2013-12-31 | Yolare Pharmaceuticals, LLC | Modified mutant collagenase and its use in fat melting and in scar reduction |
BRPI0721698A2 (pt) | 2007-05-11 | 2013-01-22 | Sigma Tau Ind Famaceutiche Riunite S P A | gel étil para a liberaÇço de ingredientes ativos cosmÉticos |
US9987221B2 (en) | 2007-08-23 | 2018-06-05 | Boston Scientific Scimed, Inc. | Injectable hydrogel compositions |
RU2492496C2 (ru) | 2007-10-26 | 2013-09-10 | Конинклейке Филипс Электроникс Н.В. | Световое детекторное устройство с выбором угла света |
US20110262508A1 (en) | 2007-11-07 | 2011-10-27 | Paul Michael Watt | Antimicrobial compositions, formulations and uses thereof |
US20100159564A1 (en) * | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
EP2130551B1 (fr) | 2008-06-02 | 2012-06-06 | Roche Diagnostics GmbH | Purification améliorée de collagénases à partir de culture liquide de Clostridium histolyticum |
US8236356B2 (en) | 2008-06-11 | 2012-08-07 | Roche Diagnostics Operations, Inc. | Growth medium for Clostridium histolyticum |
AU2009274229B2 (en) | 2008-07-21 | 2013-08-22 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
US8380531B2 (en) | 2008-07-25 | 2013-02-19 | Invivodata, Inc. | Clinical trial endpoint development process |
US20110160617A9 (en) | 2008-10-22 | 2011-06-30 | Allergan, Inc. | Clinical assessment scales and methods |
KR20110083628A (ko) | 2008-11-11 | 2011-07-20 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 셀룰라이트의 치료에 유용한 화합물 |
JP5698536B2 (ja) * | 2008-11-19 | 2015-04-08 | Meiji Seikaファルマ株式会社 | アフィニティタグが結合した融合コラゲナーゼおよびその製造法 |
WO2011109732A2 (fr) | 2010-03-05 | 2011-09-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Gels thermiques inverses et leurs utilisations |
WO2011130537A2 (fr) | 2010-04-14 | 2011-10-20 | Northwestern University | Compositions pharmaceutiques et procédés de digestion de plaques athérosclérotiques |
WO2012031245A1 (fr) | 2010-09-03 | 2012-03-08 | North Carolina Central University | Liquogel biodégradable et nanovecteurs sensible au ph |
ES2385239B1 (es) * | 2010-09-30 | 2013-06-19 | Proteos Biotech S.L.U. | Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno. |
WO2012112940A1 (fr) | 2011-02-18 | 2012-08-23 | Kythera Biopharmaceuticals, Inc. | Traitement de graisse sous-mentale |
WO2012125948A1 (fr) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions et procédés de production de collagénases clostridiennes |
TWI461214B (zh) | 2011-06-13 | 2014-11-21 | Univ Chang Gung | Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases |
KR102043476B1 (ko) | 2011-10-17 | 2019-11-12 | 사운드 써지칼 테크놀로지 엘엘씨 | 셀룰라이트를 처리하기 위한 초음파 프로브 |
PT3581199T (pt) | 2011-10-21 | 2023-08-31 | Endo Global Ventures | Métodos de tratamento ou redução de paniculopatia edematosa fibroesclerótica |
DK2802652T3 (da) | 2012-01-12 | 2019-07-15 | Endo Global Ventures | Clostridium histolyticum enzym |
JP6049862B2 (ja) | 2012-09-07 | 2016-12-21 | 株式会社 資生堂 | フィブリン3及び/又はサルコグリカンγを指標としたセルライトの評価方法及びセルライト効果薬剤の評価方法 |
EP2968107B1 (fr) | 2013-03-15 | 2019-05-08 | Mary Kay, Inc. | Compositions cosmétiques et leurs utilisations |
US20160000890A1 (en) | 2013-03-15 | 2016-01-07 | Biospecifics Technologies Corp. | Thermosensitive hydrogel collagenase formulations |
AU2014228477B2 (en) | 2013-03-15 | 2019-05-23 | Biospecifics Technologies Corporation | Treatment method and product for uterine fibroids using purified collagenase |
CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
CN114272251A (zh) | 2014-06-27 | 2022-04-05 | 玫帝托克斯股份有限公司 | 用于减少脂肪的胆酸类与盐类的制剂及用途 |
AU2017218522A1 (en) | 2016-02-08 | 2018-08-23 | OutcomeMD, Inc. | Determining a wellness, improvement, or effectiveness score |
WO2018077825A1 (fr) | 2016-10-28 | 2018-05-03 | Merz Pharma Gmbh & Co. Kgaa | Traitement de lipodystrophie gynoïde |
AU2018226820B2 (en) | 2017-03-01 | 2022-12-08 | Endo Ventures Limited | Apparatus and method for assessing and treating cellulite |
EP3601556A2 (fr) | 2017-03-28 | 2020-02-05 | Endo Ventures Limited | Methode amelioree de production de la collagenase |
-
2013
- 2013-01-10 DK DK13736040.0T patent/DK2802652T3/da active
- 2013-01-10 JP JP2014552282A patent/JP6263755B2/ja active Active
- 2013-01-10 NZ NZ766918A patent/NZ766918A/en unknown
- 2013-01-10 NZ NZ733709A patent/NZ733709A/en unknown
- 2013-01-10 EP EP13736040.0A patent/EP2802652B1/fr active Active
- 2013-01-10 NZ NZ627372A patent/NZ627372A/en unknown
- 2013-01-10 ES ES21208743T patent/ES2968836T3/es active Active
- 2013-01-10 WO PCT/US2013/020940 patent/WO2013106510A2/fr active Application Filing
- 2013-01-10 HU HUE19174182A patent/HUE057423T2/hu unknown
- 2013-01-10 AU AU2013208028A patent/AU2013208028B2/en active Active
- 2013-01-10 EP EP21208743.1A patent/EP4015627B1/fr active Active
- 2013-01-10 CA CA2970639A patent/CA2970639C/fr active Active
- 2013-01-10 NZ NZ750379A patent/NZ750379A/en unknown
- 2013-01-10 CA CA2861033A patent/CA2861033C/fr active Active
- 2013-01-10 NZ NZ718173A patent/NZ718173A/en unknown
- 2013-01-10 ES ES19174182T patent/ES2904884T3/es active Active
- 2013-01-10 PT PT13736040T patent/PT2802652T/pt unknown
- 2013-01-10 DK DK19174182.6T patent/DK3584317T5/da active
- 2013-01-10 EP EP23185957.0A patent/EP4276180A3/fr active Pending
- 2013-01-10 ES ES13736040T patent/ES2740499T3/es active Active
- 2013-01-10 MX MX2014008441A patent/MX351448B/es active IP Right Grant
- 2013-01-10 HU HUE13736040A patent/HUE046160T2/hu unknown
- 2013-01-10 EP EP19174182.6A patent/EP3584317B1/fr active Active
- 2013-01-10 BR BR112014017229-3A patent/BR112014017229B1/pt active IP Right Grant
- 2013-01-10 PT PT191741826T patent/PT3584317T/pt unknown
-
2014
- 2014-07-11 US US14/328,772 patent/US9757435B2/en active Active
-
2016
- 2016-07-28 AU AU2016208378A patent/AU2016208378B2/en active Active
- 2016-07-28 AU AU2016208384A patent/AU2016208384C1/en active Active
-
2017
- 2017-08-04 US US15/669,286 patent/US10603365B2/en active Active
- 2017-11-22 JP JP2017224394A patent/JP6496386B2/ja active Active
-
2019
- 2019-01-11 AU AU2019200192A patent/AU2019200192B2/en active Active
- 2019-02-06 JP JP2019019694A patent/JP6752309B2/ja active Active
-
2020
- 2020-03-11 US US16/816,097 patent/US11975054B2/en active Active
- 2020-08-18 JP JP2020138009A patent/JP6947888B2/ja active Active
-
2021
- 2021-08-25 AU AU2021221653A patent/AU2021221653B2/en active Active
- 2021-09-16 JP JP2021150945A patent/JP7354197B2/ja active Active
-
2023
- 2023-06-28 US US18/342,874 patent/US11879141B2/en active Active
- 2023-09-12 AU AU2023229488A patent/AU2023229488A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007089851A2 (fr) * | 2006-01-30 | 2007-08-09 | Auxilium International Holdings, Inc. | Compositions et procedes de traitement des maladies mediees par le collagene |
WO2011073925A2 (fr) * | 2009-12-15 | 2011-06-23 | Abiel S.R.L. | Collagénases de recombinaison de c. histolyticum et procédé de production de ces dernières |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2802652A4 (fr) | Enzymes de clostridium histolyticum et procédés pour les utiliser | |
HK1210831A1 (en) | Compositions and methods for detecting protease activity in biological systems | |
EP2834355A4 (fr) | Matériaux d'immobilisation d'enzyme de polysilicate-polysilicone | |
EP2866024A4 (fr) | Électrode enzymatique | |
HK1207880A1 (en) | Improved enzyme variants | |
ZA201500911B (en) | Enzymes | |
EP2880050A4 (fr) | Nouvelles enzymes, composants enzymatiques et leurs utilisations | |
EP2632949A4 (fr) | Anticorps spécifiques de clostridium difficile et leurs applications | |
GB201218831D0 (en) | Permenter and the method of fermentation | |
EP2828615A4 (fr) | Système et procédés de lasergrammétrie | |
EP2852673A4 (fr) | Procédé de sélection et microorganismes recombinants et leurs utilisations | |
HK1189302A1 (zh) | 蓄電池系統及其運用方法 | |
EP2866025A4 (fr) | Électrode enzymatique | |
GB201216649D0 (en) | Agents and methods | |
HK1198445A1 (en) | On-column enzymatic cleavage | |
AP2014008113A0 (en) | Pipeline and methods | |
HK1212375A1 (en) | Systems and methods for enzyme detection | |
SG11201508053WA (en) | Modified carbonyl reducing enzyme and gene | |
GB201309178D0 (en) | Enzyme and uses thereof | |
GB201207018D0 (en) | Enzymes | |
EP2823038A4 (fr) | Cellules souches placentaires, procédés d'isolation de ces cellules et utilisation de ces procédés | |
EP2728001A4 (fr) | Procédé de modification d'une fonction enzymatique et variant enzymatique résultant | |
SG11201501838RA (en) | Completion assembly and methods for use thereof | |
SG11201403809YA (en) | Methods for software systems and software systems using the same | |
GB201221092D0 (en) | Assemblies and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140722 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 9/52 20060101AFI20150526BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150916 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 9/52 20060101AFI20150910BHEP |
|
17Q | First examination report despatched |
Effective date: 20160830 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180625 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20181128 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ENDO GLOBAL VENTURES |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1139995 Country of ref document: AT Kind code of ref document: T Effective date: 20190615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013056193 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20190711 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20190605 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR Ref country code: PT Ref legal event code: SC4A Ref document number: 2802652 Country of ref document: PT Date of ref document: 20190910 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20190823 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190905 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20190402659 Country of ref document: GR Effective date: 20191128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2740499 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191005 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E046160 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013056193 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
26N | No opposition filed |
Effective date: 20200306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1139995 Country of ref document: AT Kind code of ref document: T Effective date: 20190605 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190605 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20221227 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20230103 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230109 Year of fee payment: 11 Ref country code: SE Payment date: 20230110 Year of fee payment: 11 Ref country code: IT Payment date: 20230113 Year of fee payment: 11 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20231228 Year of fee payment: 12 Ref country code: GB Payment date: 20231218 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20231228 Year of fee payment: 12 Ref country code: NL Payment date: 20231220 Year of fee payment: 12 Ref country code: LU Payment date: 20231218 Year of fee payment: 12 Ref country code: IE Payment date: 20231228 Year of fee payment: 12 Ref country code: FR Payment date: 20231214 Year of fee payment: 12 Ref country code: FI Payment date: 20231228 Year of fee payment: 12 Ref country code: CZ Payment date: 20231221 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231219 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240222 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20231228 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20231221 Year of fee payment: 12 Ref country code: DE Payment date: 20231215 Year of fee payment: 12 Ref country code: CH Payment date: 20240201 Year of fee payment: 12 |